ATXS - Wutah dodolan YoY (TTM) Astria Therapeutics

Revenue volatility compared to the same period last year over the TTM demonstrates Astria Therapeutics (ATXS) dependence on the success of drug trials for rare allergies, where the 0.00 level captures the current state. The business completely ignores macroeconomic fluctuations and GDP. Stability is ensured by a strong staff of immunologists who receive fair compensation for discovering treatments for severe pathologies.
Astria Therapeutics Inc (ATXS) - rincian metrik lan laporan keuangan

To select high-quality assets, it is essential for investors to evaluate cash flow stability through the lens of real business scaling. This indicator measures the percentage change in revenue over the last twelve months, which, in the context of Astria Therapeutics (ATXS) developing a drug for hereditary angioedema, allows for the determination of product commercialization rates via the year-over-year (LTM) gross revenue trend on GURU.Markets.